Myriam Labopin Selected Research

Transplantation

10/2022	Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis.
10/2022	Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT).
10/2022	Outcome of human umbilical cord blood stem cell transplantation (CBT) for acute myeloid leukemia in patients achieving first complete remission after one versus two induction courses: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
10/2022	Comparison of Outcomes after Unrelated Double-Unit Cord Blood and Haploidentical Peripheral Blood Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia: A Study on Behalf of Eurocord and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
1/2022	Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation.
1/2022	Human leukocyte antigen-haploidentical transplantation for relapsed/refractory acute myeloid leukemia: Better leukemia-free survival with bone marrow than with peripheral blood stem cells in patients ≥55 years of age.
1/2022	Impact of the Addition of Antithymocyte Globulin to Post-Transplantation Cyclophosphamide in Haploidentical Transplantation with Peripheral Blood Compared to Post-Transplantation Cyclophosphamide Alone in Acute Myelogenous Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
1/2022	Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3-ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party/European society of blood and marrow transplantation.
1/2022	Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT.
1/2022	Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Myriam Labopin Research Topics

Disease

160	Leukemia 10/2022 - 04/2002
144	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2022 - 11/2002
46	Graft vs Host Disease (Graft-Versus-Host Disease) 10/2022 - 02/2004
42	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 03/2022 - 02/2008
16	Neoplasms (Cancer) 03/2021 - 03/2015
13	Pathologic Complete Response 10/2022 - 11/2010
9	Autoimmune Diseases (Autoimmune Disease) 01/2021 - 02/2010
8	Hematologic Neoplasms (Hematological Malignancy) 08/2020 - 02/2006
7	Bronchiolitis Obliterans Syndrome 11/2021 - 05/2015
5	Residual Neoplasm 12/2020 - 09/2014
5	Chromosome Aberrations (Chromosome Abnormalities) 01/2020 - 07/2008
5	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 11/2019 - 09/2014
5	Crohn Disease (Crohn's Disease) 05/2019 - 12/2015
4	Hematologic Diseases (Blood Diseases) 01/2021 - 01/2017
3	Philadelphia Chromosome 01/2021 - 03/2015
3	Infections 01/2020 - 09/2015
3	Sickle Cell Anemia (Hemoglobin S Disease) 12/2019 - 01/2017
2	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 10/2021 - 01/2018
2	COVID-19 01/2021 - 01/2021
2	Systemic Scleroderma (Systemic Sclerosis) 01/2021 - 12/2017
2	Monosomy 01/2020 - 01/2018
2	monosomy Chromosome 7 01/2020 - 01/2018
2	Inflammation (Inflammations) 05/2019 - 01/2017
1	Cardiotoxicity 06/2021
1	Acute Promyelocytic Leukemia 01/2021
1	Diffuse Scleroderma (Progressive Systemic Sclerosis) 01/2021
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2021
1	Hyperbilirubinemia 12/2020
1	Malnutrition (Nutritional Deficiencies) 11/2020
1	Sarcoma (Soft Tissue Sarcoma) 10/2020
1	Multiple Sclerosis 01/2020
1	Bites and Stings (Sting) 01/2020
1	Bone Marrow Failure Disorders 01/2020
1	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2020
1	Cytopenia 01/2020
1	Toxoplasmosis 01/2020
1	Immune System Diseases (Immune Disorders) 10/2019
1	Arthralgia (Joint Pain) 01/2019
1	Arthritis (Polyarthritis) 01/2019
1	Hemorrhage 01/2018

Drug/Important Bio-Agent (IBA)

45	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2022 - 10/2013
24	Busulfan (Busulfex)FDA Link 01/2022 - 10/2013
19	fludarabineIBA 01/2022 - 04/2015
17	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 01/2022 - 05/2015
12	Thiotepa (Triethylenethiophosphoramide)FDA LinkGeneric 01/2022 - 01/2016
9	HLA Antigens (Human Leukocyte Antigens)IBA 01/2022 - 11/2008
6	treosulfanIBA 01/2022 - 07/2017
6	Melphalan (Alkeran)FDA LinkGeneric 01/2022 - 04/2015
5	Mycophenolic Acid (Cellcept)FDA LinkGeneric 01/2022 - 03/2016
5	Tyrosine Kinase InhibitorsIBA 01/2021 - 03/2015
5	Clofarabine (Clolar)FDA Link 08/2020 - 09/2012
4	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2022 - 07/2008
4	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2022 - 05/2015
4	Calcineurin InhibitorsIBA 01/2021 - 03/2016
4	Sorafenib (BAY 43-9006)FDA Link 03/2019 - 01/2018
3	AntigensIBA 01/2022 - 05/2019
3	Azacitidine (5 Azacytidine)FDA Link 01/2020 - 01/2016
3	SteroidsIBA 01/2017 - 04/2002
2	fms-Like Tyrosine Kinase 3IBA 01/2022 - 01/2020
2	Immunosuppressive Agents (Immunosuppressants)IBA 01/2022 - 12/2019
2	Methotrexate (Mexate)FDA LinkGeneric 01/2022 - 12/2020
2	defibrotideIBA 10/2021 - 01/2018
2	Gemtuzumab (Mylotarg)FDA Link 12/2020 - 01/2020
2	AntibodiesIBA 01/2020 - 02/2015
2	Etoposide (VP 16)FDA LinkGeneric 01/2020 - 01/2018
2	Interleukin-15 (Interleukin 15)IBA 04/2018 - 01/2018
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 04/2016 - 02/2004
1	Alkylating AgentsIBA 01/2022
1	Amsacrine (AMSA)IBA 01/2022
1	Core Binding Factor Alpha 2 SubunitIBA 10/2021
1	Transaminases (Aminotransferases)IBA 12/2020
1	Tacrolimus (Prograf)FDA LinkGeneric 10/2020
1	antineoplaston A10 (A 10)IBA 01/2020
1	Core Binding Factors (Core-Binding Factor)IBA 01/2020
1	Sulfamethoxazole Drug Combination Trimethoprim (Co-Trimoxazole)FDA LinkGeneric 01/2020
1	Rituximab (Mabthera)FDA Link 01/2020
1	Thymidine Monophosphate (TMP)IBA 01/2020
1	Phenobarbital (Luminal)FDA Link 05/2019
1	LigandsIBA 01/2019
1	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 01/2019
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2018
1	Transcription Factors (Transcription Factor)IBA 01/2018
1	CohesinsIBA 01/2018
1	Polycomb Repressive Complex 2IBA 01/2018

Therapy/Procedure

151	Transplantation 10/2022 - 04/2002
115	Stem Cell Transplantation 10/2022 - 02/2003
74	Hematopoietic Stem Cell Transplantation 10/2022 - 11/2002
43	Cell Transplantation 10/2022 - 02/2015
31	Therapeutics 01/2021 - 04/2002
19	Haploidentical Transplantation 01/2022 - 04/2015
18	Drug Therapy (Chemotherapy) 01/2022 - 06/2008
12	Homologous Transplantation 01/2020 - 11/2002
11	Bone Marrow Transplantation (Transplantation, Bone Marrow) 01/2022 - 04/2002
7	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 10/2022 - 03/2015
4	Autologous Transplantation 12/2017 - 01/2005
1	Cord Blood Stem Cell Transplantation 10/2022
1	Traction 01/2021
1	Nutritional Support (Artificial Feeding) 11/2020
1	Donor Selection 11/2019
1	Biological Therapy 05/2019